tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Amgen price target lowered to $303 from $310 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Amgen to $303 from $310 and keeps an Equal Weight rating on the shares. MariTide diabesity development “continues to dominate the conversation” and the next update from the Phase 2 trial is expected in Q4, the analyst tells investors in a Q2 earnings preview note for the Biopharma group.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1